# PT-141: a narrow clinical translation > PT-141 | Research Peptide Fundamentals research peptides | Peptide Empire — Research Peptide Fundamentals research peptides: an independent review of PT-141 or bremelanotide, central melanocortin signaling, phase 3 evidence, and label limits. **FIELD FILE / 05** Bremelanotide acts through central melanocortin receptors. The approved indication is specific. The claim boundary is firm. ## The short version PT-141 is the research name commonly used for bremelanotide, a cyclic peptide that activates melanocortin receptors in the brain. Its main clinical target is MC4R, a receptor involved in motivation, appetite, and sexual signaling. That central mechanism differs from drugs that act mainly on blood flow. Bremelanotide reached United States approval for acquired, generalized hypoactive sexual desire disorder in premenopausal women. The approval does not extend to men, postmenopausal women, general performance enhancement, or material sold as a research chemical [27]. Two phase 3 trials found statistically significant improvements in sexual desire and desire-related distress against placebo [25]. A brain-imaging study found altered processing of erotic cues and increased desire after MC4R agonism [24]. The safety burden is visible. Nausea, flushing, and headache were common in the long-term extension [26]. The label warns about temporary blood-pressure increases and restricts use in cardiovascular conditions [27]. This is a real clinical translation. It is also a narrow one. ## What it is Bremelanotide is a synthetic cyclic heptapeptide. Its ring is held by a lactam bridge. The design is related to alpha-melanocyte-stimulating hormone and to melanotan research, but the structure and approved product are distinct. The cyclic form gives the molecule a constrained shape for melanocortin receptor binding. Naming requires care. PT-141 often refers to the research compound. Bremelanotide refers to the active pharmaceutical ingredient in the approved prescription product. A shared molecule name does not make every source equivalent. The regulatory evidence belongs to the approved formulation and labeled indication [27]. Material sold outside that system lacks the same identity, purity, concentration, and surveillance guarantees. The compound acts as an MC3R and MC4R agonist. MC4R is the dominant clinical frame. It is present in hypothalamic and limbic circuits involved in sexual motivation and other drives. ## How it works Bremelanotide activates central melanocortin receptors, chiefly MC4R and also MC3R. The relevant receptors sit in brain regions that coordinate motivation, arousal, and autonomic responses. Signaling through hypothalamic circuits is thought to engage dopamine-linked pathways involved in sexual desire. This is not the same mechanism as a PDE-5 inhibitor. PDE-5 inhibition changes vascular smooth-muscle signaling and blood flow. Bremelanotide acts upstream in central neural processing. A functional imaging study in women with hypoactive sexual desire disorder found changes in amygdala-insula connectivity and other task-related activity after MC4R agonism [24]. That supports a brain-processing mechanism. The pathway is not a simple reward switch. A hamster study found MC3R and MC4R expression in dopamine neurons but did not find enhanced conditioned sexual reward after bremelanotide [23]. Animal results cannot directly settle human desire. They do show that the mechanism is more specific than a broad amplification of reward. ## What the research shows The RECONNECT program included two matched phase 3 randomized trials with 1,267 premenopausal women who had hypoactive sexual desire disorder. Bremelanotide produced statistically significant improvement in desire and reduced desire-related distress over twenty-four weeks. The integrated effect estimates were +0.35 for the desire measure and -0.33 for the distress item [25]. Statistical significance does not make the change universal. It establishes an average effect in the studied population. A randomized crossover imaging study included 31 premenopausal women with the same condition. MC4R agonism increased reported desire for as long as twenty-four hours and altered brain responses to erotic stimuli [24]. This supplies mechanistic human evidence beside the phase 3 outcomes. The open-label extension enrolled 684 women and ran for fifty-two weeks. No new safety signal emerged. Reported improvements persisted. Nausea occurred in 40.4% of participants, flushing in 20.6%, and headache in 12.0% [26]. The United States label defines the indication and pharmacology. It reports a terminal half-life of about 2.7 hours and warns of transient blood-pressure elevation [27]. A 2025 hamster study found no increase in conditioned sexual reward and no change in melanocortin-receptor expression in the tested dopamine circuit [23]. This negative animal result adds nuance. It does not cancel human clinical findings. ## Reported effects, cautions & safety Anecdotal, not clinical evidence: patient and research communities report stronger desire, greater arousal and sensitivity, easier orgasm, and sometimes no benefit. Reports from men describe spontaneous erections, but that use is outside the approved indication. Common complaints include nausea, flushing, headache, injection-site irritation, tingling, fatigue, and skin or gum darkening. These accounts vary and do not define clinical frequency. Trial data make nausea the leading tolerability issue. In the long-term extension, nausea affected 40.4% of participants, flushing 20.6%, and headache 12.0% [26]. The approved label warns that blood pressure can rise temporarily and identifies uncontrolled hypertension and known cardiovascular disease as contraindications [27]. Repeated exposure can also cause focal hyperpigmentation. Scope is part of safety. Approval covers a defined diagnosis in premenopausal women. It does not cover general enhancement or other populations [27]. Research-chemical material sits outside the approved product record. The phase 3 evidence supports a measured average effect in the indicated population [25]. It does not justify transferring the same efficacy, exposure, or safety assumptions to off-label community use. ## Where it fits in Research Peptide Fundamentals PT-141 shows how a peptide can reach clinical use through a focused neural target and a narrow indication. Mechanistic imaging supports central melanocortin action [24]. Randomized trials support changes in desire and distress [25]. Long-term follow-up defines common adverse effects [26]. The label fixes the population, warnings, and product boundary [27]. That chain is strong enough for a specific approval. It is not broad enough for every claim surrounding the research name. The distinction between central desire, physical arousal, vascular response, reward, and general performance matters. So does the distinction between an approved prescription product and unverified research material. PT-141 belongs in this hub because it shows governance working at full resolution: molecule, mechanism, trial, indication, warning, and limit. The [comparison matrix](/compare) sets that record beside less mature programs. --- Peptide Empire audits how peptide claims cross from mechanism into medicine; it is an independent literature digest, not clinical direction.